Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18015340 | 0.95 | LPL (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL22179707 | 0.88 | LPL (0.39) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29925307 | 0.86 | LPL (0.38) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL30345418 | 0.86 | TP53 (0.43) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1494499 | 0.86 | TP53 (0.43) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL4244671 | 0.86 | LPL (0.38) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL7887164 | 0.86 | LPL (0.49) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16517298 | 0.86 | LPL (0.38) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL28599147 | 0.86 | LPL (0.38) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL21117319 | 0.85 | LPL (0.38) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2026-05-19 | — | — | US | claimed |
| US-20220263102-A1 | ELIMINATING VOLTAGE DELAY AND STABILIZING IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2022-08-18 | — | — | US | claimed |
| EP-3997748-A1 | ELIMINATION OF VOLTAGE DELAY AND STABILIZATION OF IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK Batterietechnologie GmbH (DE) | 2022-05-18 | — | — | EP | claimed |
| US-7037905-B2 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2006-05-02 | — | — | US | claimed |
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | US | claimed |
| WO-2003105860-A1 | PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | claimed |
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2026-05-19 | — | — | US | disclosed |
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
| EP-4384519-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | Albert-Ludwigs-Universität Freiburg (DE) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023017152-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2023-02-16 | — | — | WO | disclosed |
| US-20220263102-A1 | ELIMINATING VOLTAGE DELAY AND STABILIZING IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2022-08-18 | — | — | US | disclosed |
| EP-3997748-A1 | ELIMINATION OF VOLTAGE DELAY AND STABILIZATION OF IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK Batterietechnologie GmbH (DE) | 2022-05-18 | — | — | EP | disclosed |
| US-20210380566-A1 | NEW ANTHELMINTIC COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2021-12-09 | — | — | US | disclosed |
| EP-1979324-A2 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER'S DISEASE, NEURODEGENERATION AND DEMENTIA | Astra Zeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007058602-A2 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, NEURODEGENERATION AND DEMENTIA. | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| US-7037905-B2 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2006-05-02 | — | — | US | disclosed |
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | US | disclosed |
| WO-2003105860-A1 | PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | disclosed |
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | LPL 4349/4885LIPG 4370/4885CA1 3755/4885 |
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | LIPE, CEL, LIPA | LPL 5/4885LIPG 8/4885CA1 771/4885 |
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | KCNN1, HCN4, KCNN2 | LPL 4624/4885LIPG 4122/4885CA1 83/4885 |
| US-20210380566-A1 | NEW ANTHELMINTIC COMPOUNDS | H1-10, HRH2, HRH4 | LPL 4363/4885LIPG 4816/4885CA1 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.